Impaired iron homeostasis in Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn 60, Issue , 2000, Pages 37-58

  Double, K L ^a   Gerlach, M ^b   Youdim, M B H ^c   Riederer, P ^b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; LACTOFERRIN; NEUROMELANIN; TRANSFERRIN;

CONFERENCE PAPER; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON KINETICS; IRON METABOLISM; IRON TRANSPORT; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; HOMEOSTASIS; HUMANS; IRON; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0034520888     PISSN: 03036995     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-3-7091-6301-6_3     Document Type: Article

References (133)

1. The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls
2. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging
3. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography
4. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson's disease
5. Intranigral iron injection induces behavioural and biochemical "parkinsonism" in rats
6. Iron accumulation in the substantia nigra in rats visualized by ultrasound
7. Iron mobilisation from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes: Possible mechanism in inflammation diseases
8. Biochemical and toxicological properties of the oxidation products of catecholamines
9. Reactive release of ferritin iron: A kinetic assay
10. Incidence and clinical profile of familial forms of Parkinson's disease. A study of 428 index-cases from a department of neurology
11. The neuromelanin of the human substantia nigra
12. The cellular distribution of transferrin, ferritin and iron in the human brain
13. Regional distribution of iron and iron-regulatory proteins in the brain in Aging and Alzheimer's disease
14. A quantitative analysis of isoferritins in select regions of aged, parkisonian and Alzheimer's diseased brains
15. Basel lipid peroxidation in substantia nigra is increased in Parkinson's disease
16. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
17. Decreased ferritin levels in brain of Parkinson's disease
18. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia
19. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study
20. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
21. In vitro studies of ferritin iron release and neurotoxicity
22. The role of iron in 6-hydroxydopamine neurotoxicity
23. The significance of neuromelanin in Parkinson's disease
24. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins
25. An autoradiographic study of the uptake and distribution of iron by the brain of the young rat
26. Expression of lactoferrin receptors is increased in the mesenceplon of patients with Parkinson's disease
27. 125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys
28. 125I]-transferrin binding sites on perikarya of melaninzed neurons of the substantia nigra is decreased in Parkinson's disease
29. Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice
30. Inflammatory pathogenesis in Alzheimer's disease: Biological mechanisms and cognitive sequeli
31. Altered brain metabolism of iron as a cause of neurodegenerative diseases?
32. Brain iron and other trace metals in neurodegenerative diseases
33. Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra
34. Iron in the parkinsonian substantia nigra
35. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrastriatal projections and differential neuron susceptibility in Parkinson's disease
36. Oxidative stress: Free radical production in neural degeneration
37. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study
38. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease
39. Oxidation pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
40. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia
41. The effect of age on the non-haemin iron in the human brain
42. Anti-inflammatory mediations do not decrease Alzheimer's disease neuropatholgy
43. Iron and free radical reactions: Two aspects of antioxidant protection
44. Regulation of the iron regulatory proteins by reactive nitrogen and oxygen species
45. Time course of dopaminergic cell death and changes in iron, ferritin and transferrin levels in the rat substantia nigra after 6-hydroxydopamine (6-OHDA) lesioning
46. Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease
47. Neuronal vulnerability in Parkinson's disease
48. Demonstration and characterisation of the iron regulatory protein in human brain
49. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease
50. Brain iron and ferritin in Parkinson's disease and Alzheimer's disease
51. Iron-melanin complex in substantia nigra of Parkinsonian brains: An X-ray microanalysis
52. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease
53. Oxidative mechanisms in nigral cell death in Parkinson's disease
54. Nonsteroidal anti-inflammatory drugs and cognitive function
55. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
56. Lacto-transferrin immunocytochemistry in Alzheimer and normal human brain
57. The role of transition metals in the pathogenesis of Parkinson's disease
58. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
59. 3 within the ventrolateral striatum causes a chronic disturbance of the integrative function within the limbic part of the ventral striatum
60. Excessive iron accumulation in the brain: A possible potential source of neurodegeneration in Parkinson's disease
61. Captopril induces iron release from ferritin and oxidative stress
62. The iron binding protein lactrotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: A comparative immunohistochemical analysis
63. Cellular distribution of the iron-binding protein lactoferrin in the mesencephalon of Parkinson's disease cases
64. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): A putative nigral endotoxin of relevence to Parkinson's disease
65. Dopamine, 6-hydroxydopamine, iron and dioxygen - Their mutual interactions and possible implication in the development of Parkinson's disease
66. Altered systemic iron metabolism in Parkinson's disease
67. Iron and neuromelanin in Parkinson's disease
68. Complex I, iron, and ferritin in Parkinson's disease substantia nigra
69. Oxygen toxicity protecting enzymes in Parkinson's disease: Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus
70. The epidemiology of Parkinson's disease in an Australian population
71. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease
72. Arthritus and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies
73. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
74. Iron homeostasis, oxidative stress and DNA damage
75. Mitochondrial dysfunction in Parkinson's disease
76. Release of iron from ferritin by semiquinone, anthracycline, bibyridyl and nitroaromatic radicals
77. The superoxide-dependent transfer of iron from ferritin to transferrin and lactoferrin
78. Transferrin receptors in the Parkinsonian midbrain
79. 2 oxidation of dopamine
80. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: A histochemical and neurochemical study
81. Dopamine-melanin induces apoptosis in PC12 cells; Possible implications for the etiology of Parkinson's disease
82. Parkinson's disease: A disorder due to nigral glutathione deficiency
83. The effect of melanin on iron associated decomposition of hydrogen peroxide
84. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
85. Neuromelanin synthesis in rat and human substantia nigra
86. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
87. Nitric oxide mediates iron release from ferritin
88. Melanin formation by human brain in vitro
89. Magnetic resonance imaging evidence of decreased putamental iron content in idiopathic Parkinson's disease
90. A selective increase in particular superoxide dismutase activity in parkinsonian substantia nigra
91. A marker of oxyradical-mediated DNA damage (8-hydroxy-2' deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain
92. Photosensitization of melanins: A comparative study
93. Interaction of radicals from water radiolysis with melanins
94. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease
95. Progressive changes in striatal dopaminergic markers, nigral volume and rotational behaviour following iron infusion into the rat substantia nigra
96. Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration
97. Infusion of iron into the rat substantia nigra: Nigral pathology and dose dependent loss of dopaminergic markers
98. Iron- and manganese-catalysed autoxidation of dopamine in the presence of L-cysteine: Possible insights into iron- and manganese-mediated dopaminergic neurotoxicity
99. Oxidation of dopamine in the presence of cysteine: Characterization of new toxic products
100. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: An electron paramagnetic resonance spectroscopy study
101. Glutathione-related enzymes in brain in Parkinson's disease
102. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia
103. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
104. Abnormal localisation of iron regulatory protein in Alzheimer's disease
105. On the function of neuromelanin
106. Increased iron(III) and total iron content in post mortem substantia nigra of parkinsonian brain
107. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
108. Risk of Alzheimer's disease and duration of NSAID use
109. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African Green monkey: Evidence from proton microprobe elemental microanalysis
110. Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation
111. Copper, ceruloplasmin, superoxide dismutase and iron paramaters in Parkinson's disease
112. Genetic and environmental and environmental risk factors in Parkinson's disease
113. Nuclear microscope analysis in Alzheimer's and Parkinson's disease: A review
114. Intranigral injected iron progressively reduces striatal dopamine metabolism
115. Basel ganglia iron content in Parkinson's disease measured with magnetic resonance
116. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease
117. Activated microglia cause superoxide-mediated release of iron from ferritin
118. Is Parkinson's disease a progressive siderosis of substantia nigra resulting from iron and melanin induced neurodegeneration?
119. Iron in brain function and dysfunction with emphasis on Parkinson's disease
120. Neurotoxicity of iron and nitric oxide
121. Iron-melanin interaction and Parkinson's disease
122. The possible role of iron in the etiopathology of Parkinson's disease
123. The enigma of neuromelanin in Parkinson's disease substantia nigra
124. Oxygen free radicals and neurodegeneration in Parkinson's disease: A role for nitric oxide
125. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems
126. Total and paramagnetic metals in human substantia nigra and its neuromelanin
127. The chemical characterization of melanin contained in substantia nigra of human brain
128. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain
129. Effects of L-cysteine on the oxidation chemistry of dopamine: New reaction pathways of potential relevance to idiopathic Parkinson's disease